IFNG and infection: Indeed, an earlier phase 1 clinical trial had showed the vaccine to be well tolerated and capable of generating adequate IFNγ T-cell responses, but poor anti-dengue neutralizing antibody responses [78], raising concerns about incomplete protection and breakthrough infections.